Status:
COMPLETED
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Lead Sponsor:
Corewell Health West
Collaborating Sponsors:
Van Andel Research Institute
Conditions:
Cutaneous Neurofibromas
Neurofibromatosis Type 1
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the research study is intended to use specimens (such as tissue) and medical information in the Laboratory of Musculoskeletal Oncology at the Van Andel Research Institute for laboratory...
Detailed Description
Skin tumors in Neurofibromatosis Type 1 (NF1) are very common and diminish quality of life. Apart from surgery, very few treatment options exist. In comparison to other types of tumors in NF1, skin tu...
Eligibility Criteria
Inclusion
- Any subject with an established diagnosis NF1 and CNFs. The diagnosis may be based on clinical criteria or genetic testing.
- Age \>18 years.
Exclusion
- Adults with diminished decision-making capacity with no defined legal guardian.
- Prisoners.
- Pregnant women.
- 3\) Breastfeeding mothers.
Key Trial Info
Start Date :
May 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT02777775
Start Date
May 1 2016
End Date
June 1 2025
Last Update
July 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spectrum Health Hospital Group
Grand Rapids, Michigan, United States, 49503